Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) disclosed a share repurchase in a Next Day Disclosure Return filed on 23 March 2026.

• Transaction details: On 23 March 2026, the company repurchased 107,200 H shares on the Hong Kong Stock Exchange at prices ranging from HKD 22.28 to HKD 22.68 per share, for a total consideration of HKD 2.41 million. All repurchased shares are designated for cancellation.

• Capital structure: – H shares in issue remain at 35.93 million after the transaction. – A shares in issue stand at 190.20 million; 3.85 million A shares are held as treasury shares. – Combined, the company’s issued ordinary share capital (excluding treasury shares) totals 226.13 million shares. The latest repurchase equates to 0.0474 % of this figure.

• Repurchase mandate utilisation: – The current mandate, approved on 10 June 2025, permits the buy-back of up to 3.91 million shares. – Cumulative repurchases under the mandate have reached 2.71 million shares, representing 6.92 % of the issued share capital on the mandate date, leaving an authorised balance of approximately 1.21 million shares.

• Regulatory note: Following the buy-back, the company is subject to a moratorium on issuing new shares or selling treasury shares until 22 April 2026, in accordance with Hong Kong Listing Rules.